by David Wallace Key Points Rusfertide achieved clinical response in 77% of patients compared to 33% with placebo in the Phase 3 VERIFY trial The drug significantly reduced the number of blood draws needed each year and decreased PV-related symptoms Rusfertide maintained hematocrit levels below 45% and reduced or eliminated the need for phlebotomy Safety […]